Zymeworks Inc.
ZYME
Rank in Stocks
#5565
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase,... Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
Share Price
$30.81
Last synced: 2026-11-09
Market Cap
$2.22B
Change (1 day)
3.98%
Change (1 year)
56.55%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Zymeworks Inc. (ZYME)
Category
Healthcare
EPS for Zymeworks Inc. (ZYME)
EPS as of June 2026 TTM: $-2.02
According to Zymeworks Inc.'s latest financial reports, its current EPS (TTM) is $-2.02. At the end of 2025 the company had an EPS of $-1.08, an increase over its 2024 EPS of $-1.62.
EPS history for Zymeworks Inc. from 2014 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-2.02 | 87.04% |
| 2025 | $-1.08 | -33.33% |
| 2024 | $-1.62 | -5.81% |
| 2023 | $-1.72 | -190.05% |
| 2022 | $1.91 | -147.04% |
| 2021 | $-4.06 | 13.41% |
| 2020 | $-3.58 | -6.53% |
| 2019 | $-3.83 | 203.97% |
| 2018 | $-1.26 | 157.14% |
| 2017 | $-0.49 | -71.51% |
| 2016 | $-1.72 | 77.32% |
| 2015 | $-0.97 | 49.23% |
| 2014 | $-0.65 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -875.25% |
US
|
|
| $-7.07 | 250.00% |
US
|
|
| $-5.29 | 161.88% |
AU
|
|
| $12.88 | -737.63% |
BE
|
|
| $21.56 | -1,167.33% |
NL
|
Questions about Zymeworks Inc.'s earnings per share (EPS)
What is Zymeworks Inc.'s earnings per share (EPS)?
Zymeworks Inc.'s earnings per share (EPS) over the last twelve months is $-2.02, as of Jun 2026.
What was Zymeworks Inc.'s earnings per share (EPS) in 2025?
In 2025, Zymeworks Inc.'s earnings per share (EPS) was $-1.08, compared with $-1.62 in 2024.
How has Zymeworks Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Zymeworks Inc.'s earnings per share (EPS) was highest in 2022 ($1.91) and lowest in 2021 ($-4.06).
How does Zymeworks Inc.'s earnings per share (EPS) compare with similar companies?
Zymeworks Inc.'s earnings per share (EPS) ($-2.02) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.